| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/10428190802510323 |
| P8608 | Fatcat ID | release_ojcsclmu2bbmjdrnosz7vivgtq |
| P698 | PubMed publication ID | 19052979 |
| P50 | author | Ryszard Andrzejak | Q9324571 |
| Tomasz Wróbel | Q56989878 | ||
| Andrzej Szuba | Q58324793 | ||
| Grzegorz Mazur | Q70883320 | ||
| Kazimierz Kuliczkowski | Q93204621 | ||
| Angelika Chachaj | Q95947582 | ||
| Jolanta Antonowicz-Juchniewicz | Q114290808 | ||
| P2093 | author name string | Justyna Dzietczenia | |
| P2860 | cites work | Arginine metabolism: nitric oxide and beyond | Q24531285 |
| Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase | Q27633661 | ||
| Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis | Q28182592 | ||
| Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction | Q28235815 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Nitric oxide as a signaling molecule in the vascular system: an overview. | Q33794569 | ||
| Arginine nutrition in development, health and disease | Q33821447 | ||
| Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase | Q33865641 | ||
| State of the arg: protein methylation at arginine comes of age. | Q34084396 | ||
| Association of asymmetric dimethylarginine and endothelial dysfunction | Q35600450 | ||
| ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease | Q35603923 | ||
| ADMA and oxidative stress | Q35603932 | ||
| Endogenous production of nitric oxide synthase inhibitors | Q36380990 | ||
| Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials | Q36381000 | ||
| The redox regulation of thiol dependent signaling pathways in cancer. | Q36683582 | ||
| Nitric oxide in shock | Q36835542 | ||
| Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? | Q37026846 | ||
| L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells | Q40213948 | ||
| Live and let die: asymmetric dimethylarginine and septic shock | Q40271492 | ||
| Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study | Q40397164 | ||
| The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. | Q40576129 | ||
| Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. | Q41128788 | ||
| Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia | Q42538581 | ||
| Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus | Q43796150 | ||
| Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 | ||
| Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine | Q43850042 | ||
| The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis | Q44294204 | ||
| A proteomic analysis of arginine-methylated protein complexes | Q44611061 | ||
| Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis | Q45207667 | ||
| Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension | Q46626286 | ||
| The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance | Q46851299 | ||
| Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. | Q51720782 | ||
| Short-term Pulmonary Vasodilation With l -Arginine in Pulmonary Hypertension | Q54162413 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 2316-2320 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Asymmetric dimethylarginine in hematological malignancies: a preliminary study | |
| P478 | volume | 49 |
| Q55107043 | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| Q37299599 | Asymmetric dimethylarginine attenuates serum starvation-induced apoptosis via suppression of the Fas (APO-1/CD95)/JNK (SAPK) pathway. |
| Q57781463 | Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases |
| Q96953131 | Determination of Endothelial Nitric Oxide Synthase Gene Polymorphism and Plasma Asymmetric Dimethyl Arginine Concentrations in Patients with Lung Cancer |
| Q87403330 | Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer |
| Q24611412 | The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism |
Search more.